| The following article features coverage from the NCCN 2022 Annual Conference. Click here to read more of Cancer Therapy Advisor’s conference coverage. |
First-line pembrolizumab plus nab-paclitaxel may improve some outcomes, when compared with chemotherapy alone, in patients with advanced triple-negative breast cancer (TNBC), a meta-analysis suggests.
Pembrolizumab plus nab-paclitaxel improved progression-free survival (PFS) compared with nab-paclitaxel alone. The combination also improved overall survival (OS) when compared with carboplatin or docetaxel alone.
These findings were presented in a poster at the NCCN 2022 Annual Conference.
Continue Reading
The meta-analysis included data from 19 publications of 8 randomized, controlled trials. Researchers compared pembrolizumab plus nab-paclitaxel with single-agent or combination first-line therapies in patients with locally recurrent, inoperable, or metastatic TNBC.
The results suggested that PFS was significantly better with pembrolizumab plus nab-paclitaxel than with nab-paclitaxel alone (hazard ratio [HR], 0.57; 95% CI, 0.35-0.94).
However, pembrolizumab plus nab-paclitaxel did not provide superior PFS when compared with atezolizumab plus nab-paclitaxel (HR, 0.80; 95% CI, 0.46-1.40), carboplatin alone (HR, 0.66; 95% CI, 0.33-1.29), or docetaxel alone (HR, 0.68; 95% CI, 0.36-1.30).
OS was significantly better with pembrolizumab plus nab-paclitaxel than with carboplatin alone (HR, 0.41; 95% CI, 0.21-0.83) or docetaxel alone (HR, 0.35; 95% CI, 0.19-0.67).
However, pembrolizumab plus nab-paclitaxel did not provide superior OS when compared with atezolizumab plus nab-paclitaxel (HR, 0.82; 95% CI, 0.46-1.44) or nab-paclitaxel alone (HR, 0.63; 95% CI, 0.39-1.02).
Taking these findings together, the researchers concluded that pembrolizumab plus nab-paclitaxel is an effective first-line treatment strategy for patients with locally recurrent, inoperable, or metastatic TNBC.
Disclosures: This research was supported by Merck Sharp & Dohme Corp. Some study authors declared affiliations with biotech, pharmaceutical, and/or device companies. Please see the original reference for a full list of disclosures.
Read more of Cancer Therapy Advisor’s coverage of NCCN 2022 by visiting the conference page.
Reference
Haiderali A, Huang M, Pan W, et al. Pembrolizumab plus chemotherapy for first-line treatment of advanced triple-negative breast cancer – A network meta-analysis. Presented at NCCN 2022 Annual Conference; March 31 – April 2, 2022. Abstract HSR22-145.
